Psilocybin Heads Into Anorexia Trials, Where the Bar for Progress Is a 5% Death Rate

Scientific American's Science Quickly devoted an episode to psilocybin research in anorexia nervosa, with host Rachel Feltman interviewing freelance health journalist Alexandra Pattillo, who wrote a recent feature on the work ^[14]. The reason to pay attention is not the compound. It is the baseline: roughly 5 percent of people with anorexia nervosa die within four years of diagnosis ^[3].

That number does most of the analytical work here. Anorexia also carries a suicide rate 18 times that of the general population, and survivors face organ damage and other consequences of malnutrition that can raise mortality risk years after they enter remission ^[4][5]. The condition sits inside a broader problem: a 2020 report cited in the episode found that as much as 9 percent of the U.S. population, nearly 31 million people, will have an eating disorder in their lifetime, and that someone dies as a direct consequence of an eating disorder every 52 minutes ^[1][2]. At that rate, the figure works out to roughly 10,100 deaths a year [c3d].

The other half of the arithmetic is what current care does. Cognitive behavioural therapy and antidepressants make a large difference for some patients, but research suggests around half will not achieve sustained recovery ^[6]. Pattillo describes the standard menu for eating disorders as narrow: CBT, SSRIs or other antidepressants, sometimes antipsychotics ^[12]. Notably, the transcript we were given cuts off mid-sentence as she begins to say how well those work, so the specific number she quotes is not in our material.

The psychedelic context is familiar and worth restating without enthusiasm. Psilocybin, the active ingredient in magic mushrooms, is one of the classic psychedelics alongside LSD, DMT and mescaline ^[8]. Pattillo notes these substances have been used by Indigenous communities in South America, Asia and parts of Europe for centuries, and entered modern laboratories in the 1950s and 1960s before political backlash and new drug policies halted the work in the late 1960s and early 1970s ^[13][9]. She credits a team at Johns Hopkins with reviving the field in the early 2000s, since when dozens of animal and human trials have looked at PTSD, anxiety, depression and addiction, with promising findings from studies that were mostly small and limited in scope ^[10][11].

Anorexia is a newer target, and the honest description of the evidence is thin. Feltman's framing is that the research is in its very earliest stages, with a few study subjects reporting striking results ^[7]. Our source material contains no trial sizes, no dosing regimens, no control conditions and no follow-up durations, which means there is nothing here to weigh against existing care.

What to watch: which endpoint the trials actually report. Weight restoration is easy to measure and historically easy to achieve in the short term; the harder outcomes are eating-disorder cognition and sustained remission, which is precisely where about half of patients currently fail ^[6]. Also watch how investigators handle physiological risk in patients who are malnourished, since organ damage is already part of the disease picture ^[5]. A condition this lethal makes small early signals look large. It also makes underpowered studies a poor basis for changing anything.